Comparison of outcomes with low-dose anti-thymocyte globulin, basiliximab or no induction therapy in pediatric kidney transplant recipients: A retrospective study

Pediatric Transplantation

Volumn 12, Issue 1, 2008, Pages 32-39

  Baron, Pedro W ^a,d   Ojogho, Okechukwu N ^a   Yorgin, Peter ^a   Sahney, Shobha ^a   Cutler, Drew ^a   Ben Youssef, Ramzi ^a   Baqai, Waheed ^a   Weissman, Jill ^a   Franco, Edson ^a   Zuppan, Craig ^b   Concepcion, Waldo ^c  

^a LOMA LINDA UNIVERSITY MEDICAL CENTER   (United States)

^b LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c STANFORD UNIVERSITY   (United States)

^d Transplantation Institute   (United States)

Author keywords

Acute rejection; Anti thymocyte globulin; Basiliximab; Induction therapy; Pediatric kidney transplant

Indexed keywords

BASILIXIMAB; CYCLOSPORIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADOLESCENT; ADULT; ARTICLE; CHILD; CYTOMEGALOVIRUS INFECTION; DRUG DOSE REDUCTION; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT SURVIVAL; HIGH RISK PATIENT; HUMAN; KIDNEY ALLOGRAFT; KIDNEY GRAFT; LOW DRUG DOSE; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; RECIPIENT; RETROSPECTIVE STUDY; VIRUS PNEUMONIA;

ADOLESCENT; ANTIBODIES, MONOCLONAL; ANTILYMPHOCYTE SERUM; CHILD; FEMALE; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; RECOMBINANT FUSION PROTEINS; RETROSPECTIVE STUDIES; T-LYMPHOCYTES;

EID: 37848999059     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2007.00764.x     Document Type: Article

References (24)

1. Brennan DC, Flavin K, Lowell JA, et al. A randomized, double-blinded comparison of thymoglobulin versus atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation 1999 : 67 : 1011.
2. Djamali A, Turc-Baron C, Portales P, et al. Low dose antithymocyte globulins in renal transplantation: Daily versus intermittent administration based on T-cell monitoring. Transplantation 2000 : 69 : 799.
3. Peddi VR, Bryant M, Roy-Chaudhury P, Woodle ES, First MR. Safety, efficacy, and cost analysis of thymoglobulin induction therapy with intermittent dosing based on CD3+ lymphocyte counts in kidney and kidney-pancreas transplant recipients. Transplantation 2002 : 73 : 1514.
4. Hardinger KL, Schnitzler MA, Miller B, et al. Five-year follow up of thymoglobulin versus ATGAM induction in adult renal transplantation. Transplantation 2004 : 78 : 136.
5. Hardinger KL, Bohl DL, Schnitzler MA, Lockwood M, Storch GA, Brennan DC. A randomized, prospective, pharmacoeconomic trial of tacrolimus versus cyclosporine in combination with thymoglobulin in renal transplant recipients. Transplantation 2005 : 80 : 41.
6. Hardinger KL, Schnitzler MA, Koch MJ, et al. Thymoglobulin induction is safe and effective in live-donor renal transplantation: A single center experience. Transplantation 2006 : 81 : 1285.
7. Buchler M, Hurault de Ligny B, Madec C, Lebranchu Y. Induction therapy by anti-thymocyte globulin (rabbit) in renal transplantation: A 1-yr follow-up of safety and efficacy. Clin Transplant 2003 : 17 : 539.
8. Lilliu H, Brun-Strang C, Le Pen C, et al. Cost-minimization study comparing simulect vs. thymoglobulin in renal transplant induction. Clin Transplant 2004 : 18 : 247.
9. Ducloux D, Kazory A, Challier B, et al. Long-term toxicity of antithymocyte globulin induction may vary with choice of agent: A single-center retrospective study. Transplantation 2004 : 77 : 1029.
10. Gaber AO, First MR, Tesi RJ, et al. Results of the double-blind, randomized, multicenter, phase III clinical trial of thymoglobulin versus atgam in the treatment of acute graft rejection episodes after renal transplantation. Transplantation 1998 : 66 : 29.
11. Brophy PD, Thomas SE, McBryde KD, Bunchman TE. Comparison of polyclonal induction agents in pediatric renal transplantation. Pediatr Transplant 2001 : 5 : 174.
12. Benfield MR, McDonald R, Sullivan EK, Stablein DM, Tejani A. The 1997 Annual Renal Transplantation in Children Report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Pediatr Transplant 1999 : 3 : 152.
13. Smith JM, Nemeth TL, McDonald RA. Current immunosuppressive agents in pediatric renal transplantation: Efficacy, side-effects and utilization. Pediatr Transplant 2004 : 8 : 445.
14. Ault BH, Honaker MR, Osama Gaber A, et al. Short-term outcomes of thymoglobulin induction in pediatric renal transplant recipients. Pediatr Nephrol 2002 : 17 : 815.
15. Hastings MC, Wyatt RJ, Lau KK, et al. Five years' experience with thymoglobulin induction in a pediatric renal transplant population. Pediatr Transplant 2006 : 10 : 805.
16. Pierrat A, Gravier E, Saunders C, et al. Predicting GFR in children and adults: A comparison of the Cockcroft-Gault, Schwartz, and modification of diet in renal disease formulas. Kidney Int 2003 : 64 : 1425.
17. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999 : 55 : 713.
18. Agha IA, Rueda J, Alvarez A, et al. Short course induction immunosuppression with thymoglobulin for renal transplant recipients. Transplantation 2002 : 73 : 473.
19. Wong W, Agrawal N, Pascual M, et al. Comparison of two dosages of thymoglobulin used as a short-course for induction in kidney transplantation. Transpl Int 2006 : 19 : 629.
20. Ojogho O, Ben-Youssef R, Franco E, et al. Antibody induction therapy with low dose anti-thymocyte globulin in simultaneous pancreas-kidney transplantation. Am J Transplant 2006 : 6 : 525.
21. Di Filippo S. Anti-IL-2 receptor antibody vs. polyclonal anti-lymphocyte antibody as induction therapy in pediatric transplantation. Pediatr Transplant 2005 : 9 : 373.
22. Khositseth S, Matas A, Cook ME, Gillingham KJ, Chavers BM. Thymoglobulin versus ATGAM induction therapy in pediatric kidney transplant recipients: A single-center report. Transplantation 2005 : 79 : 958.
23. Montini G, Murer L, Ghio L, et al. One-year results of basiliximab induction and tacrolimus associated with sequential steroid and MMF treatment in pediatric kidney transplant recipient. Transpl Int 2005 : 18 : 36.
24. Offner G, Broyer M, Niaudet P, et al. A multicenter, open-label, pharmacokinetic/pharmacodynamic safety, and tolerability study of basiliximab (Simulect) in pediatric de novo renal transplant recipients. Transplantation 2002 : 74 : 961.